Get the Stockscreener App
3.61
2.17%
-0.08
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Altimmune Inc stock is traded at $3.61, with a volume of 1.80M.
It is down -2.17% in the last 24 hours and down -14.66% over the past month.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
See More
Previous Close:
$3.69
Open:
$3.62
24h Volume:
1.80M
Relative Volume:
0.33
Market Cap:
$292.80M
Revenue:
$409.00K
Net Income/Loss:
$-101.35M
P/E Ratio:
-2.2012
EPS:
-1.64
Net Cash Flow:
$-71.49M
1W Performance:
-11.52%
1M Performance:
-14.66%
6M Performance:
-45.63%
1Y Performance:
-40.72%
1-Day Range:
$3.58
$3.7152
1-Week Range:
$3.58
$4.14
52-Week Range:
$2.90
$11.16
Altimmune Inc Stock (ALT) Company Profile
Name
Altimmune Inc
Sector
Industry
Phone
(240) 654-1450
Address
910 CLOPPER ROAD, GAITHERSBURG, MD
Compare ALT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALT
Altimmune Inc
|
3.61 | 299.28M | 409.00K | -101.35M | -71.49M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Altimmune Inc Stock (ALT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Resumed | Goldman | Sell |
| Feb-28-25 | Initiated | William Blair | Mkt Perform |
| Jan-08-25 | Initiated | Stifel | Buy |
| Nov-12-24 | Initiated | UBS | Buy |
| Apr-29-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-24-24 | Initiated | Goldman | Neutral |
| Mar-22-23 | Downgrade | Goldman | Buy → Neutral |
| Dec-01-22 | Initiated | Goldman | Buy |
| Dec-29-21 | Resumed | Jefferies | Buy |
| Jun-02-21 | Initiated | H.C. Wainwright | Buy |
| Feb-11-21 | Initiated | Guggenheim | Buy |
| Dec-14-20 | Initiated | Jefferies | Buy |
| Nov-12-20 | Reiterated | B. Riley Securities | Buy |
| Sep-25-20 | Initiated | B. Riley FBR | Buy |
| Aug-14-20 | Initiated | Evercore ISI | Outperform |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jul-28-20 | Initiated | JMP Securities | Mkt Outperform |
| Feb-24-20 | Resumed | ROTH Capital | Buy |
| Jul-19-19 | Initiated | ROTH Capital | Buy |
| Oct-09-17 | Initiated | Piper Jaffray | Overweight |
View All
Altimmune Inc Stock (ALT) Latest News
What catalysts could drive Altimmune Inc. stock higher in 2025Low Risk Updates For Beginners - jammulinksnews.com
What institutional investors are buying Altimmune Inc. stockFree Stock Data Feed Backed By Experts - jammulinksnews.com
Altimmune, Inc. (ALT) Stock Analysis: Exploring The 376.96% Potential Upside - DirectorsTalk Interviews
Is Altimmune Inc. reversing from oversold territorySafe Momentum Strategy With Trend Analysis - Newser
Market reaction to Altimmune Inc.’s recent newsFree Triple Return Setup with Risk Control - Newser
Applying chart zones and confluence areas to Altimmune Inc.Weekly Trend Screener with Momentum Picks - Newser
Altimmune Bets Big On Next-Gen Obesity And Liver Drugs - Finimize
Levi & Korsinsky Launches Fraud Investigation on Behalf of Altimmune, Inc. (ALT) Shareholders - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc.ALT - PR Newswire
Published on: 2025-07-31 05:27:57 - Newser
How to use a screener to detect Altimmune Inc. breakoutsTechnical Reversal Pattern Summary and Tracker - Newser
Why Altimmune Inc. stock attracts strong analyst attentionShort-Term Sector Movement Forecast Generator - Newser
How sentiment analysis helps forecast Altimmune Inc.Chart Pattern Recognition for Profit Timing - Newser
Regression analysis insights on Altimmune Inc. performanceWeekly Chart-Based Forecast for Traders - Newser
Is Altimmune Inc. stock reversal real or fakeEntry Opportunity Screener with Confirmation - Newser
Altimmune, Inc. Securities Lawsuit Investigation - Claim Depot
Real Time Data Flags Unusual Activity in Altimmune Inc.Oversold Bounce Stock Play Ideas Gain Attention - beatles.ru
ALT Investor Notice: Levi & Korsinsky Investigates Altimmune, Inc. For Securities Law Violations - ACCESS Newswire
Altimmune, Inc. (ALT) Under Investigation for Potential Securities Law ViolationsContact Levi & Korsinsky Today - ACCESS Newswire
Altimmune Inc. stock daily chart insightsBuy Zone Strategy with Pattern Recognition - Newser
How Altimmune Inc. stock performs during market volatilityShort-Term Trade Setup with Forecast Insight - Newser
Should I hold or sell Altimmune Inc. stock in 2025Unlock expert market analysis instantly - jammulinksnews.com
What are analysts’ price targets for Altimmune Inc. in the next 12 monthsHigh-impact investment strategies - jammulinksnews.com
Altimmune Inc. Stock Chart Analysis: Bullish or Bearish Pattern FormingWatchlist Winner Update - Newser
Altimmune Gears Up to Report Q2 Earnings: Here's What to Expect - MSN
Altimmune, Inc. (NASDAQ:ALT) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Lost Money on Altimmune, Inc. (ALT)? Possible FraudContact Levi & Korsinsky Today - ACCESS Newswire
What analysts say about Altimmune Inc. stockExceptional risk-adjusted gains - PrintWeekIndia
Levi & Korsinsky Investigating Whether Altimmune, Inc. (ALT) Misled InvestorsSecurities Law Violations Possible - ACCESS Newswire
Altimmune: Potential Tough Road Ahead Amid Fierce Competition (Rating Downgrade) (ALT) - Seeking Alpha
Altimmune Inc (ALT) Stock: A Year of Stock Market Dynamics - investchronicle.com
Lost Investment in Altimmune, Inc. (ALT)? Levi & Korsinsky Launches Securities Fraud Investigation - ACCESS Newswire
Is Altimmune Inc. a good long term investmentPowerful growth strategies - Autocar Professional
Altimmune Inc. Stock Analysis and ForecastRapid wealth multiplication - jammulinksnews.com
What drives Altimmune Inc. stock priceConsistent triple-digit returns - jammulinksnews.com
Shareholders Alert: Investigation Into Altimmune, Inc. (ALT)Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire
Lost Money on Altimmune, Inc. (ALT)? Contact Levi & Korsinsky About Fraud Investigation - ACCESS Newswire
Levi & Korsinsky Reminds Altimmune, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities LawsALT - ACCESS Newswire
Investors in Altimmune, Inc. (ALT) Warned of Potential Securities FraudContact Levi & Korsinsky Today - Newsfile
(ALT) Technical Pivots with Risk Controls - news.stocktradersdaily.com
ALT ALERT: Ongoing Investigation Into Altimmune, Inc.Contact Levi & Korsinsky - ACCESS Newswire
Securities Litigation as a Strategic Tool: Lessons from Altimmune's Legal Challenges and the Role of the Schall Law Firm - AInvest
ALT Investors Have Opportunity to Join Altimmune, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
Altimmune Inc Stock (ALT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Altimmune Inc Stock (ALT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| WEAVER GREGORY L | Chief Financial Officer |
Mar 13 '25 |
Buy |
5.20 |
10,000 |
51,996 |
10,000 |
| Garg Vipin K | President and CEO |
Feb 02 '25 |
Option Exercise |
0.00 |
18,950 |
0 |
363,364 |
| Garg Vipin K | President and CEO |
Feb 01 '25 |
Option Exercise |
0.00 |
16,545 |
0 |
351,645 |
| Garg Vipin K | President and CEO |
Jan 30 '25 |
Option Exercise |
0.00 |
26,775 |
0 |
342,696 |
| Harris Matthew Scott | Chief Medical Officer |
Feb 02 '25 |
Option Exercise |
0.00 |
7,775 |
0 |
84,564 |
| Harris Matthew Scott | Chief Medical Officer |
Feb 01 '25 |
Option Exercise |
0.00 |
6,166 |
0 |
78,898 |
| Harris Matthew Scott | Chief Medical Officer |
Jan 30 '25 |
Option Exercise |
0.00 |
9,275 |
0 |
74,000 |
| Roberts M Scot | Chief Scientific Officer |
Feb 02 '25 |
Option Exercise |
0.00 |
7,775 |
0 |
75,536 |
| Roberts M Scot | Chief Scientific Officer |
Feb 01 '25 |
Option Exercise |
0.00 |
6,166 |
0 |
69,562 |
| Roberts M Scot | Chief Scientific Officer |
Jan 30 '25 |
Option Exercise |
0.00 |
9,275 |
0 |
62,921 |
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):